1363 related articles for article (PubMed ID: 21942919)
1. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
2. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
McCormack PL; Joura EA
Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
[TBL] [Abstract][Full Text] [Related]
3. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.
McCormack PL
Drugs; 2014 Jul; 74(11):1253-83. PubMed ID: 25022951
[TBL] [Abstract][Full Text] [Related]
4. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
5. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males.
Garnock-Jones KP; Giuliano AR
Drugs; 2011 Mar; 71(5):591-602. PubMed ID: 21443282
[TBL] [Abstract][Full Text] [Related]
6. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
[TBL] [Abstract][Full Text] [Related]
7. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
8. A human papillomavirus vaccine.
Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):65-6. PubMed ID: 16977280
[TBL] [Abstract][Full Text] [Related]
9. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.
McKeage K; Romanowski B
Drugs; 2011 Mar; 71(4):465-88. PubMed ID: 21395359
[TBL] [Abstract][Full Text] [Related]
10. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
[TBL] [Abstract][Full Text] [Related]
11. A review of clinical trials of human papillomavirus prophylactic vaccines.
Schiller JT; Castellsagué X; Garland SM
Vaccine; 2012 Nov; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).
Siddiqui MA; Perry CM
Drugs; 2006; 66(9):1263-71; discussion 1272-3. PubMed ID: 16827602
[TBL] [Abstract][Full Text] [Related]
13. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.
Reisinger KS; Block SL; Lazcano-Ponce E; Samakoses R; Esser MT; Erick J; Puchalski D; Giacoletti KE; Sings HL; Lukac S; Alvarez FB; Barr E
Pediatr Infect Dis J; 2007 Mar; 26(3):201-9. PubMed ID: 17484215
[TBL] [Abstract][Full Text] [Related]
14. Developing an HPV vaccine to prevent cervical cancer and genital warts.
Bryan JT
Vaccine; 2007 Apr; 25(16):3001-6. PubMed ID: 17289220
[TBL] [Abstract][Full Text] [Related]
15. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
16. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
[TBL] [Abstract][Full Text] [Related]
17. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.
Villa LL; Costa RL; Petta CA; Andrade RP; Paavonen J; Iversen OE; Olsson SE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; Krogh Gv; Lehtinen M; Malm C; Tamms GM; Giacoletti K; Lupinacci L; Railkar R; Taddeo FJ; Bryan J; Esser MT; Sings HL; Saah AJ; Barr E
Br J Cancer; 2006 Dec; 95(11):1459-66. PubMed ID: 17117182
[TBL] [Abstract][Full Text] [Related]
18. Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
Gilson R; Nugent D; Bennett K; Doré CJ; Murray ML; Meadows J; Haddow LJ; Lacey C; Sandmann F; Jit M; Soldan K; Tetlow M; Caverly E; Nathan M; Copas AJ
Health Technol Assess; 2020 Sep; 24(47):1-86. PubMed ID: 32975189
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
[TBL] [Abstract][Full Text] [Related]
20. [The first vaccine against cancer: the human papillomavirus vaccine].
Bősze P
Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
